Indoco Remedies Ltd

{"amount":0.2}

{"actualRevenue":4846700000,"estimateRevenue":4622000000,"revenueSurprise":224700000,"revenueSurprisePercent":4.861531804413674,"actualEPS":-1.07,"estimateEPS":-0.909,"surprise":-0.161,"surprisePercent":17.71177117711771}

{"actualRevenue":4756100000,"estimateRevenue":3965000000,"revenueSurprise":791100000,"revenueSurprisePercent":19.95208070617907,"actualEPS":-3.01,"estimateEPS":-3.838,"surprise":0.8279999999999998,"surprisePercent":-21.57373632100052}

{"actualRevenue":4453600000,"estimateRevenue":4569000000,"revenueSurprise":-115400000,"revenueSurprisePercent":-2.525716787043117,"actualEPS":-3.2,"estimateEPS":0.404,"surprise":-3.604,"surprisePercent":-892.0792079207921}

{"description":"Indoco Remedies' March quarter loss narrowed to ₹22 crore from ₹40 crore, revenue rose 22% to ₹476 crore and EBITDA turned positive at ₹50.2 crore, lifting the stock over 13% on May 7.","url":"https://www.cnbctv18.com/market/indoco-remedies-shares-rally-13-pc-q4-results-loss-halves-ebitda-returns-to-profit-ws-l-19900862.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Indoco Remedies shares rose over 8.5% on January 30, 2026, following USFDA approval for its Lacosamide Oral Solution, a generic of Vimpat. This approval enhances its US generics portfolio and reflects the company's commitment to global healthcare. The stock peaked at ₹229.64 before settling at ₹217.47, still above its opening price.","url":"https://www.cnbctv18.com/market/indoco-remedies-share-price-gains-usfda-approval-lacosamide-oral-solution-ws-l-19836967.htm","sentiment":"Positive","domain":"CNBCTV18"}